.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
CREDENCE randomized patients with type 2 diabetes and albuminuric chronic kidney disease to canagliflozin or placebo on top of renin–angiotensin system blockade. Canagliflozin significantly reduced the risk of the composite of kidney failure, doubling of serum creatinine, or renal or cardiovascular death. The trial was important because it showed that SGLT2 inhibition can slow progression of diabetic kidney disease independently of its glucose-lowering effect. For internal-medicine practice, the study reinforced the need to identify CKD early and use albuminuria as more than a diagnostic marker—it is also a major risk-stratification tool. In eligible patients, nephroprotective therapy should be layered on to blood-pressure control, renin–angiotensin system blockade, glycemic management and cardiovascular risk reduction. Monitoring volume status, kidney function and adverse effects remains part of safe implementation. CREDENCE helped shift the treatment model from reactive management of advanced diabetic nephropathy to earlier disease modification intended to delay kidney failure and reduce cardiovascular burden.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
CREDENCE randomized patients with type 2 diabetes and albuminuric chronic kidney disease to canagliflozin or placebo on top of renin–angiotensin system blockade. Canagliflozin significantly reduced the risk of the composite of kidney failure, doubling of serum creatinine, or renal or cardiovascular death. The trial was important because it showed that SGLT2 inhibition can slow progression of diabetic kidney disease independently of its glucose-lowering effect. For internal-medicine practice, the study reinforced the need to identify CKD early and use albuminuria as more than a diagnostic marker—it is also a major risk-stratification tool. In eligible patients, nephroprotective therapy should be layered on to blood-pressure control, renin–angiotensin system blockade, glycemic management and cardiovascular risk reduction. Monitoring volume status, kidney function and adverse effects remains part of safe implementation. CREDENCE helped shift the treatment model from reactive management of advanced diabetic nephropathy to earlier disease modification intended to delay kidney failure and reduce cardiovascular burden.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
Yesterday
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
2 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
2 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
2 days back
